MIRAMAR, Fla., July 23, 2026
HCW Biologics Inc. announced a significant advancement in the development of its proprietary tetravalent second-generation T-cell engager (TCE) program after requesting a Type B pre-IND meeting with the U.S. Food and Drug Administration (FDA) to discuss the regulatory and clinical development strategy for its lead investigational candidate HCW11-018b. The company expects to begin Phase 1 clinical trials during the first half of 2027, marking an important step in expanding innovative immunotherapies for solid tumors. Built using HCW Biologics’ proprietary TRBC drug development platform, HCW11-018b is designed to target human tissue factor-expressing cancers, including gynecologic and pancreatic cancers, while simultaneously activating the immune system to improve anti-tumor responses. The company also reported progress in developing a streamlined, cost-efficient cGMP manufacturing process, supporting future clinical development and commercialization of the therapy.
FDA Regulatory Progress Supports Clinical Development
HCW Biologics’ request for a Type B pre-IND meeting with the FDA represents a key regulatory milestone as the company prepares its first-in-human clinical program. During the meeting, the company intends to discuss its proposed clinical trial design, nonclinical safety studies, chemistry, manufacturing and controls (CMC) package, and overall regulatory pathway for HCW11-018b. According to the company, extensive preclinical studies have demonstrated encouraging results, including strong antigen-specific anti-tumor activity, favorable pharmacokinetic characteristics, broad therapeutic potential, and an encouraging tolerability profile in animal models. Unlike many earlier-generation T-cell engagers, HCW11-018b was specifically engineered to improve efficacy against solid tumors, an area where traditional T-cell engager therapies have historically faced significant challenges. Company Founder and Chief Executive Officer Dr. Hing C. Wong stated that the investigational therapy demonstrated remarkable anti-tumor activity and the ability to penetrate the tumor microenvironment while producing potent activity against pancreatic cancer models.
Next-Generation T-Cell Engager Designed for Solid Tumors
CW11-018b is the lead candidate in HCW Biologics’ proprietary Big BiTE™ Tetravalent T-Cell Engager Program, a next-generation immunotherapy platform developed to overcome limitations associated with first-generation bispecific T-cell engagers. The investigational therapy combines multiple functional components into a single molecule, including a tissue factor-targeting BiTE, IL-15 immune stimulation, and a TGF-β trap, enabling simultaneous targeting of tumor cells, activation of CD8-positive T cells, and reduction of immunosuppression within the tumor microenvironment. In extensive laboratory and animal studies, HCW11-018b demonstrated robust antigen-specific tumor killing, enhanced immune cell activation, sustained anti-tumor responses, improved infiltration of immune cells into solid tumors, and importantly, showed no evidence of triggering cytokine release syndrome within the therapeutic dose range. The therapy is intended to be administered through subcutaneous injection, providing a potentially convenient treatment option for patients with advanced solid tumors.
Advertisement
Manufacturing Platform Positions Program for Future Growth
In addition to its clinical progress, HCW Biologics announced major advances in manufacturing capabilities supporting the future development of HCW11-018b. The company has established a robust, streamlined, and cost-efficient manufacturing process capable of producing high-quality cGMP material for clinical studies and eventual commercial production. The manufacturing platform utilizes high-producing recombinant CHO cell lines together with a proprietary monoclonal antibody purification process designed to improve production efficiency while reducing manufacturing costs compared with conventional approaches. The required monoclonal antibody is currently being produced under Good Manufacturing Practice (GMP) standards by a leading contract development and manufacturing organization (CDMO). HCW Biologics believes this scalable manufacturing strategy will support the long-term development of its broader immunotherapy pipeline while accelerating the transition of HCW11-018b into clinical testing. With growing pharmaceutical industry interest in second-generation T-cell engager therapies, particularly for difficult-to-treat solid tumors, HCW Biologics believes its proprietary platform has the potential to address major unmet medical needs while expanding future partnership and commercialization opportunities.
Source:HCW Biologics press release
